The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
The evolving landscape of drug products containing nanomaterials in the United States
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
DLS and zeta potential – What they are and what they are not?
Bhattacharjee, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.017 · Cited by 4,702
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Particle size-dependent organ distribution of gold nanoparticles after intravenous administration
De Jong, W. H., Hagens, W. I., Krystek, P., Burger, M. C., Sips, A. J. A. M., & Geertsma, R. E. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.12.037 · Cited by 1,615
Nanosuspensions as particulate drug formulations in therapy
Müller, R. H., Jacobs, C., & Kayser, O. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00118-6 · Cited by 1,370
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Techniques for physicochemical characterization of nanomaterials
Lin, P.-C., Lin, S., Wang, P. C., & Sridhar, R. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.11.006 · Cited by 708
Powers, K. W., Brown, S. C., Krishna, V. B., Wasdo, S. C., Moudgil, B. M., & Roberts, S. M. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj099 · Cited by 605
Nanopharmaceuticals (part 1): products on the market
Weissig, V., Pettinger, T., & Murdock, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s46900 · Cited by 591
Liposomes: Technologies and Analytical Applications
Jesorka, A., & Orwar, O. (2008) · Annual Review of Analytical Chemistry · doi:10.1146/annurev.anchem.1.031207.112747 · Cited by 569
Tumour-targeted nanomedicines: principles and practice
Lammers, T., Hennink, W. E., & Storm, G. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604483 · Cited by 542
Sapsford, K. E., Tyner, K. M., Dair, B. J., Deschamps, J. R., & Medintz, I. L. (2011) · Analytical Chemistry · doi:10.1021/ac200853a · Cited by 538
Self-citationTheranostic Nanomedicine for Cancer
Sumer, B., & Gao, J. (2008) · Nanomedicine · doi:10.2217/17435889.3.2.137 · Cited by 478
Warheit, D. B. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfm279 · Cited by 419
Characterization of Nanoparticles for Therapeutics
Hall, J. B., Dobrovolskaia, M. A., Patri, A. K., & McNeil, S. E. (2007) · Nanomedicine · doi:10.2217/17435889.2.6.789 · Cited by 409
Powers, K. W., Palazuelos, M., Moudgil, B. M., & Roberts, S. M. (2007) · Nanotoxicology · doi:10.1080/17435390701314902 · Cited by 383
Anderson, W., Kozak, D., Coleman, V. A., Jämting, Å. K., & Trau, M. (2013) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2013.02.030 · Cited by 373
Characterization of Nanoparticles Intended for Drug Delivery
(2011) · Methods in Molecular Biology · doi:10.1007/978-1-60327-198-1 · Cited by 358
Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications
Rizzo, L. Y., Theek, B., Storm, G., Kiessling, F., & Lammers, T. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.02.020 · Cited by 336
Poste, G. H., Bucana, C. D., Raz, A., Bugelski, P. J., Kirsh, R. L., & Fidler, I. J. (1982) · PubMed · Cited by 309
Nanomedicine in cancer therapy: Innovative trends and prospects
Blanco, E., Hsiao, A., Mann, A. P., Landry, M. G., Meric‐Bernstam, F., & Ferrari, M. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01941.x · Cited by 265
Role of Nanotechnology in Pharmaceutical Product Development
Devalapally, H., Chakilam, A., & Amiji, M. M. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20875 · Cited by 230
Dendrimer-based Macromolecular MRI Contrast Agents: Characteristics and Application
Kobayashi, H., & Brechbiel, M. W. (2003) · Molecular Imaging · doi:10.1162/15353500200303100 · Cited by 202
The cost of new drug discovery and development.
Dickson, M., & Gagnon, J. P. (2004) · PubMed · Cited by 186
New perspectives in nanomedicine
Thorley, A. J., & Tetley, T. D. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.06.008 · Cited by 171
Nanomaterial characterization: considerations and needs for hazard assessment and safety evaluation
Boverhof, D. R., & David, R. M. (2009) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-009-3103-3 · Cited by 158
FDA's Approach to Regulation of Products of Nanotechnology
Hamburg, M. A. (2012) · Science · doi:10.1126/science.1205441 · Cited by 152
"Characterization of Nanoparticles Intended for Drug Delivery"
Gabor, F. (2011) · Scientia Pharmaceutica · doi:10.3797/scipharm.br-11-01 · Cited by 142
Tyner, K. M., Bancos, S., & Stevens, D. L. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s72580 · Cited by 114
Self-citationIn Vitro and In Vivo Characterizations of Pegylated Liposomal Doxorubicin
Jiang, W., Lionberger, R. A., & Yu, L. X. (2011) · Bioanalysis · doi:10.4155/bio.10.204 · Cited by 113
Product quality for nanomaterials: current U.S. experience and perspective
Tyner, K. M., Zou, P., Yang, X., Zhang, H., Cruz, C. N., & Lee, S. L. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1338 · Cited by 77
Self-citationLinkov, P. A., Artemyev, M. V., Efimov, А. Е., & Nabiev, I. R. (2013) · Nanoscale · doi:10.1039/c3nr02372a · Cited by 66
Keene, A. M., Peters, D., Rouse, R. L., Stewart, S. R., Rosen, E. T., & Tyner, K. M. (2012) · Nanomedicine · doi:10.2217/nnm.11.125 · Cited by 59
Self-citationConsiderations When Submitting Nanotherapeutics to FDA/CDER for Regulatory Review
Tyner, K. M., & Sadrieh, N. K. (2010) · Methods in molecular biology · doi:10.1007/978-1-60327-198-1_3 · Cited by 57
Self-citationKeene, A. M., & Tyner, K. M. (2011) · Journal of Nanoparticle Research · doi:10.1007/s11051-011-0268-4 · Cited by 57
Self-citationNanomaterials and nanotechnologies: methods of analysis and control
Gmoshinski, I. V., Sa, K., Popov, V. O., Dzantiev, B. B., Zherdev, A. V., Demin, V. F., & Buzulukov, Y. P. (2013) · Russian Chemical Reviews · doi:10.1070/rc2013v082n01abeh004329 · Cited by 56
Wu, Y. C., Petrochenko, P. E., Chen, L., Wong, S. Y., Absar, M. S., Choi, S. H., & Zheng, J. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.03.029 · Cited by 44
Nanomedicine: a pharma perspective
Brown, P. D. N., & Patel, P. R. (2014) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1288 · Cited by 36
The need for rules and regulations
Helmus, M. N. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.165 · Cited by 35
Bancos, S., Tsai, D., Hackley, V. A., et al. (2012) · ISRN Nanotechnology · doi:10.5402/2012/454072 · Cited by 31
Bartlett, J. A., Brewster, M., Brown, P., Cabral-Lilly, D., Cruz, C. N., David, R., Eickhoff, W. M., Haubenreisser, S., Jacobs, A., Malinoski, F., et al. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9701-9 · Cited by 25
Self-citationJahn, M., Mrestani, Y., Langguth, P., & Neubert, R. H. H. (2007) · Electrophoresis · doi:10.1002/elps.200600559 · Cited by 11
Cited by
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Current hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi-Fainaro, R., Florindo, H. F., & Vicent, M. J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 657
Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors
Gagliardi, A., Giuliano, E., Venkateswararao, E., Fresta, M., Bulotta, S., Awasthi, V., & Cosco, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.601626 · Cited by 571
Risks, Release and Concentrations of Engineered Nanomaterial in the Environment
Giese, B., Klaessig, F., Park, B., Kaegi, R., Steinfeldt, M., Wigger, H., von Gleich, A., & Gottschalk, F. (2018) · Scientific Reports · doi:10.1038/s41598-018-19275-4 · Cited by 429
Metadata
- Authors
- D'Mello, S. R., Cruz, C. N., Chen, M.-L., Kapoor, M., Lee, S. L., & Tyner, K. M.
- Venue
- Nature Nanotechnology
- Published
- 2017-04-24
- Volume
- 12
- Issue
- 6
- Pages
- 523-529
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- OpenAlex
- W2606017739
- Cited by
- 345
- References
- 48
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.